ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Care

Fujifilm to spend $5bn to become global contract drugmaker

Opportunity seen in outsourcing trend similar to chip industry

Fujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)

TOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.

The Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more